The aura6000 system showed a 65% responder rate at 12 months in patients with obstructive sleep apnea, defined as achieving ...

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement ...

Results from the Phase III MYR301 trial show that 36% of patients who achieved undetectable hepatitis delta virus levels when ...

Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application ...

PE: What alternate strategies would have a better impact on reducing drug costs? Mendelsohn: Pushing for lower out-of-pocket ...

Sanofi announced an expansion of its partnership with McLaren Racing. The two companies, alongside United Autosports, are ...

Chip Parkinson, CEO, GiftHealth, explains how AI-powered data integration is bringing new hope to patients by revealing ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

Blake Powers, CEO, medigi, explains how digital tools, AI, and automation are streamlining access to biosimilars and cell and gene therapies, signaling a shift toward more tech-enabled, ...

Selarsdi, a biosimilar to Stelara, is approved for adult and pediatric psoriatic arthritis, plaque psoriasis, Crohn disease, ...